Neuroimaging studies in subjects at genetic risk of developing Alzheimer&apos;s disease: the role of neuroimaging to reveal the endophenotype by Berti, Valentina
 
 
 
 
 
 
DOTTORATO DI RICERCA IN 
"NEUROSCIENZE" 
 
CICLO XXV 
 
COORDINATORE Prof. Massacesi Luca 
 
 
 
Neuroimaging studies in subjects at genet ic r isk of developing Alzheimer’s 
disease: the role of neuroimaging to reveal the endophenotype. 
 
 
 
 
 
 
 Dottorando        Tutore 
 Dott. Berti Valentina      Prof. Pupi Alberto 
 
__________________      ________________ 
          (firma)               (firma) 
 
 
 
 
Anni 2010/2012 
 
  
	   2 
Table of contents 
Table of contents ------------------------------------------------------------------------ 2 
Introduction ------------------------------------------------------------------------------ 3 
Alzheimerʼs disease ----------------------------------------------------------------------- 3 
Alzheimer’s disease genetics ------------------------------------------------------------- 5 
Early onset familial Alzheimer’s disease ------------------------------------------------- 6 
Late onset Alzheimerʼs disease ---------------------------------------------------------- 7 
Endophenotypes in Alzheimer’s disease ----------------------------------------------- 15 
Maternal family history of AD ------------------------------------------------------------ 17 
Hypotheses ----------------------------------------------------------------------------- 23 
Materials and Methods ---------------------------------------------------------------- 24 
Subjects ----------------------------------------------------------------------------------- 24 
MRI acquisition and processing --------------------------------------------------------- 25 
18F-FDG PET acquisition and processing --------------------------------------------- 26 
11C-PiB PET acquisition and processing ---------------------------------------------- 26 
Statistical analysis ------------------------------------------------------------------------ 27 
Results ---------------------------------------------------------------------------------- 29 
MRI ---------------------------------------------------------------------------------------- 29 
18F-FDG PET ----------------------------------------------------------------------------- 32 
11C-PiB PET ------------------------------------------------------------------------------ 35 
Discussion ------------------------------------------------------------------------------ 36 
Conclusion ------------------------------------------------------------------------------ 38 
References ------------------------------------------------------------------------------ 39 
 
  
	   3 
Introduction 
Alzheimerʼs disease 
Alzheimerʼs disease (AD) is one of the most common illnesses in later life and the most 
common type of dementia, accounting for 60% to 80% of cases. AD is clinically 
characterized by progressive memory loss and cognitive impairment: usually the 
disease begins with difficulty in remembering names and recent events as earliest 
symptoms, and later symptoms include impaired judgment, disorientation, confusion, 
behavior changes and trouble speaking, swallowing and walking [McKhann et al., 
1984]. 
AD is one of the most pressing healthcare problems of the 21st century, with 
prevalence of dementia from 6% to 10% in adults aged 65 years and older 
[Alzheimerʼs Association 2008]; with the population of older adults increasing, the 
number of cases will continue to increase every year [Alzheimerʼs Association 2008]. 
Understanding the risk factors for AD is crucial to reduce disease occurrence or at 
least to slow its development [Brookmeyer et al., 1998]. 
At present, the clinical diagnosis of AD cannot be estabilished until the progressive 
cognitive deficits has affected patientʼs social and professional life [McKhann et al., 
1984]; this clinical threshold varies greatly between individuals, depending on patientʼs 
premorbid cognitive and intellectual level and is to some extent arbitrary. This greatly 
limits the potential for early intervention and prevention research [Lansbury et al., 
2004]. Furthermore, it is estimated that between 50% and 90% of dementia cases are 
left undiagnosed by standard clinical examinations [Hebert et al., 2003]. 
The definitive diagnosis of AD is possible only through post-mortem brain examination 
showing the presence of specific pathologic lesions: intracellular neurofibrillary tangles 
(NFT), amyloid beta (Aβ) deposition in the form of extracellular senile plaques and 
blood vessel deposits, associated with neuronal and synaptic loss, and atrophy in 
specific areas of the brain [Mirra et al., 1991]. These AD-related neuropathological 
changes begin years before the onset of clinical symptoms of dementia [Price et al., 
1999]. 
During the preclinical phase, as plaque and tangle load increase, a selective synaptic 
and neuronal loss of vulnerable cortical pyramidal neurons occurs, leading to the first 
symptoms of dementia [Morrison et al., 2007]. The brain regions most vulnerable in AD 
	   4 
are the medial temporal lobes (including hippocampus, transentorhinal and entorhinal 
cortex, and subiculum) [Braak et al., 1991, 1996]. The pyramidal cells anatomically 
connected to the entorhinal cortex (EC) and the CA1 and subiculum regions of the 
hippocampus are particularly prone to NFT formation and degeneration, whereas 
primary sensory-motor and occipital areas and the cerebellum exhibit minimal 
neuronal loss [Braak et al., 1991, 1996; Delacourte et al., 1999]. Disruption of the 
pyramidal neurons in the perforant path is thought to disconnect the hippocampus 
from the rest of the cortex, strongly contributing to the decline in memory observed in 
early AD [Hyman et al., 1984]. There is an association between NFT staging and the 
severity of clinical status in AD [Delacourte et al., 1999]. NFTs originate in the medial 
temporal lobe, which plays a critical role in the neural control of memory functions, 
then begin to cluster in the adjacent inferior temporal and posterior cingulate cortex in 
mild AD, further disrupting episodic and autobiographic memory, and eventually 
disrupting the parieto-temporal and prefrontal association cortices, which are involved 
in the neural control of perception, attention, and language, in moderate and then 
severe dementia [Braak et al., 1996; Delacourte et al., 1999]. Despite an initial 
predilection for the neocortex, Aß depositions are also found in the medial temporal 
lobes at later stages of disease [Arriagada et al., 1992]. For many years, the 
aggregation of large Aß fibrils was considered the key event in AD pathogenesis and 
the main determinant of neuronal degeneration [Selkoe et al., 1997]. A recent 
reformulation of the amyloid cascade hypothesis states that Aß oligomers, not fibrillar 
Aß, confer greater neurotoxicity to neurons by disrupting nerve signaling pathways 
and subsequently causing neuronal cell death [Lambert et al., 1998]. 
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Alzheimer’s disease genetics 
AD, as many other neurodegenerative disorders, is a genetically complex disease 
associated with multiple pathogenetic factors. Although largely influenced by genetic 
factors, the pathogenesis of AD is by far more elaborate, involving aging mechanisms 
and other age-related pathological conditions (i.e., cerebrovasular deterioration), 
epigenetic phenomena and environmental factors (i.e. nutrition). 
The genetic dysfunction in AD includes several mutational loci and susceptibility loci, 
distributed across the human genome, probably converging in a common pathogenic 
mechanism that leads to premature neuronal death, in which mitochondrial DNA 
mutations may contribute, too. 
A feature of AD, which is common to many neurodegenerative disorders, is the 
presence of both familial (rare and usually characterized by an earlier onset of disease 
symptoms) and non-familial (more common and with later onset of disease symptoms) 
forms. Although the latter form is frequently described as “sporadic”, there is 
increasing evidence suggesting that a large proportion of these cases are actually 
influenced by genetic factors. Recent estimates showed a heritability (measure of the 
proportion by which phenotypic variation is determined by genetic variation) of AD 
between 60% and 80% [Gatz et al., 2006, Pedersen et al., 2001], indicating that 
genetic factors play a crucial role in determining the risk of late-onset AD (LOAD). 
 
The research of the heritable component of AD so far has found four established AD 
genes (APP, PSEN1, PSEN2, APOE) and many potential susceptibility loci, none of 
which however has been proven to significantly modify disease risk. In the following 
chapters, we will discuss both the established and potential genetic factors involved in 
the pathogenesis of AD. 
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Early onset familial Alzheimer’s disease 
Rare AD cases (<5%) occur with a Mendelian pattern of inheritance, and usually show 
an early (<65 years), or sometimes very early (<50 years), age of onset; this form of 
AD, because of its typical familial accumulation and autosommal-dominant inheritance 
pattern, is known as “early onset familial AD” (EOFAD), and is caused by mutations in 
three genes, all of which alter the production of Aβ, one of the neuropathological 
hallmarks of AD [Tanzi et al., 2005]. The mutated genes leading to EOFAD are located 
in the amyloid precursor protein (APP) gene [Goate et al., 1991], or in the genes 
encoding the proteins that forms the active site of the γ-secretase complex: presenilin 
1 (PSEN1) [Sherrington et al. 1995] and presenilin 2 (PSEN2) [Rogaev et al., 1995] 
(Table 1). 
Even if EOFAD accounts for a little fraction of all AD cases, the knowledge of its 
genetic factors has been crucial in the development and support of the “amyloid 
hypothesis”, according to which a dysregulation of the production and function of Aβ 
is the initializing event in the pathogenic cascade leading to neurodegeneration and 
dementia [Hardy et al., 2002]. Moreover, these genes have provided encouragement 
for the discovery of amyloid-modifying medications and immunization therapies. 
 
 
Table 1. Genetic findings for EOFAD. 
 
Gene Location Relevance to AD pathogenesis 
APP  
[Goate et 
al., 1991] 
21q21.3 Increase in Aβ production or Aβ 42/Aβ 40 ratio; 
mutations in the Aβ sequence or close to the 
band γ-secretase site of APP; locus duplications 
PSEN1 
[Sherrington et 
al., 1995] 
14q24.3 Increase in Aβ 42/Aβ 40 ratio; mutations 
throughout molecule; enzymatic role in γ-
secretase complex 
PSEN2 
[Rogaev et al., 
1995] 
1q31–42 Increase in Aβ 42/Aβ 40 ratio; mutations 
throughout molecule; enzymatic role in γ -
secretase complex 
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Late onset Alzheimerʼs disease 
Late onset Alzheimerʼs disease (LOAD) accounts for the vast majority of AD cases; it 
appears later in life (usually > 60 years) and, despite its high heritability [Gatz et al., 
2006, Pedersen et al., 2001], it shows a less evident genetic association than EOFAD. 
This may be due to a combination of factors, including the complexity of the disease, 
its slow progression, patientsʼ old age, the concomitance of other age-related medical 
illnesses, and the lack of established standard criteria for incipient AD.  
Although all these difficulties, several different genes thought to have a substantial 
impact on AD predisposition have been identified, including the well-known 
Apolipoprotein E (ApoE) gene [Gatz et al., 2006]; most of them affect various pathways 
likely to be involved in the production, aggregation and removal of Aβ (Figure 1). 
However, the non-ApoE-related LOAD genes show a modest risk effect, with odds-
ratio (OR) of 1.2, as compared to the OR of 3-4 for the ApoE gene. 
 
Table 2 summarizes the most significant data on genetics of LOAD, including the Top 
Results Gene list of the AlzGene database, a publicly available database 
(http://www.alzgene.org), which systematically collects, summarizes and meta-
analyzes all genetic association studies published in the field of AD [Bertram et al., 
2008]. This database includes LOAD genes identified both with candidate-gene 
approach (studies focusing on certain genes based on some prior hypothesis 
regarding their potential involvement in the disease process) and with genome-wide 
association approach, a large-scale genotyping technology that enables more 
comprehensive and unbiased analyses [Bertram et al., 2009]. 
The functional relevance of all these potential AD susceptibility loci may not only lead 
to a better understanding of the pathogenic processes driving to neurodegeneration in 
AD, but may also help to pinpoint novel treatments for AD. 
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Table 2. Genetics findings for LOAD 
 
Gene Polymorphism location OR Relevance to AD pathogenesis 
ApoE 
[Kim et 
al., 2009] 
ε2,ε3,ε4 19q13.2 3,81 • increased AD risk and decreased 
age at onset in ε4 carriers;  
• increased accumulation of Aβ42 
and binding to tau protein 
CHRNB2 
[Kawamat
a et al., 
2002, 
Cook et 
al., 2004] 
rs4845378 1q21.3 0,67 • reduced AD risk in T-allele 
carriers;  
• nicotinic cholinergic receptors 
could contribute to cognitive 
performance during aging [Zoli et 
al., 1999], with an age-dependent 
decrease of receptor subunits in 
the cortex, particularly the 
hippocampus [Tohgi et al., 1998]; 
• evidence in LOAD of loss of 
cholinergic neurons and reduction 
of nicotinic cholinergic receptors 
[Oddo et al., 2006] 
ACE [Li et 
al., 2008, 
Thornton-
Wells et 
al., 2008] 
I/D, rs1800764, 
rs4291 and 
rs4343 
17q23 0,87 • ACE-1 protein can degrade 
secreted Aβ in vitro [Hu et al., 
2001, Hemming et al., 2005]; 
• ACE levels have been reported to 
be increased in AD brains in 
proportion to the parenchymal Aβ 
[Miners et al., 2008]; 
• Role in blood pressure regulation 
(vascular hypothesis suggested 
for AD pathogenesis [Takeda et 
al., 2008, Ohrui et al., 2004]). 
CH25H 
[Reiman 
et al., 
2007, 
Morgan et 
al., 2007, 
Li et al., 
2008b] 
rs13500 10q23 1,44 • part of lipid metabolism, as well as 
ApoE;  
• the risk-associated CH25H 
haplotype leads to increased CSF 
concentration of lathosterol, a 
metabolic precursor of 
cholesterol, to higher brain Aβ 
load and to lower Aβ 1-42 CSF 
levels in normal elderly subjects 
[Papassotiropoulos et al., 2005]. 
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Gene Polymorphism location OR Relevance to AD pathogenesis 
CST3 
[Sun et 
al., 2008, 
Sundelof 
et al., 
2008] 
rs1064039 20p11.2 1,28 • A mutation in CST3 gene has 
been associated also with amyloid 
angiopathy [Schnittger et al., 
2003]; 
• cystatin c binds to Aβ [Vinters et 
al., 1990] and inhibits Aβ fibril 
formation in vitro and in vivo 
[Sastre et al., 2004, Kaeser et al., 
2007]. 
GAB2 
[Reiman 
et al., 
2007, 
Sleegers 
et al., 
2009] 
rs10793294 11q13.4
–q13.5 
0,69 • GRB-associated binding protein 2 
is a member of a family of 
scaffolding/adapter proteins that 
are involved in multiple pathway, 
in particular in the transduction of 
cytokines and growth receptor 
signalling [Sarmay et al., 2006].  
• increased Tau phosphorylation 
and formation of neurofibrillary 
tangles [Reiman et al., 2007]. 
SORL1 
[Rogaeva 
et al., 
2007, Lee 
et al., 
2008] 
SORL1-18ex26 11q24 0,7 • SORL1 gene encodes for a protein 
that modulates subcellular 
trafficking of APP; 
• Reduced expression of SORL1 
leads to releasing of APP into 
endosomal pathways, where it is 
subjected to beta- and gamma-
secretase cleavage with 
subsequent production of 
amyloid-beta.; 
• SORL1 protein also belongs to a 
superfamily of low-density 
lipoprotein receptors (SorLA/LR11) 
that bind ApoE and are implicated 
in cholesterol metabolism and 
atherogenesis; 
• There is evidence for reduced 
SORL1 expression in the brains of 
patients with AD [Dodson et al., 
2006], associated to increased 
amyloid-beta production [Kolsch 
et al., 2008]. 
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Gene Polymorphism location OR Relevance to AD pathogenesis 
TF [van 
Rensburg 
et al., 
1993] 
rs1049296 3q21 1,18 • Iron dysregulation promotes 
neurodegeneration via the 
generation of reactive oxygen 
species [Brewer et al., 2007];  
• Increased iron levels in AD brains  
[Loeffler et al., 1995], associated 
with plaques and NFTs [Smith et 
al., 1997]; 
• Iron might also modulate the 
aggregation of 
hyperphosphorylated tau into 
insoluble paired helical filaments, 
the core component of NFTs 
[Yamamoto et al., 2002]. 
MAPT [Li 
et al., 
2008] 
rs2471738 17q21 1,24 • MAPT gene encodes for tau 
protein;  
• MAPT gene mutations have been 
associated with several 
neurodegenerative disorders such 
as AD, Pick’s disease, 
frontotemporal dementia, cortico-
basal degeneration and 
progressive supranuclear palsy; 
• Discordant results about its role in 
AD risk [Mukherjee et al., 2007]; 
PRNP 
[Casadei 
et al., 
2001] 
rs1799990 20p13 0,88 • Prion protein is the major 
determinant of familial and 
sporadic prion diseases (such as 
Creutzfeldt–Jakob disease), 
characterized by rapidly 
progressing neurodegeneration 
with spongiosis and amyloid 
plaques;  
• Aβ-positive plaques in AD brains 
often contain prion protein 
deposits; 
• In APP-PRNP double-transgenic 
mice prion protein might promote 
plaque formation in AD by 
increasing Aβ aggregation 
[Schwarze-Eicker et al., 2005] 
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Gene Polymorphism location OR Relevance to AD pathogenesis 
MTHFR 
[Seripa et 
al., 2003, 
Anello et 
al., 2004] 
rs1801131 1p36.3 1,13 • MTHFR gene codes for 5,10-
methylenetetrahydofolate 
reductase, which converts 5,10 
methylenetetrahydrofolate to 5-
methyltetrahydrofolate. 
• Despite contrasting results were 
reported, the systematic meta-
analysis of the AlzGene database 
reported an association with 
LOAD. 
 
IL1B 
[Deniz-
Naranjo et 
al., 2008] 
rs1143634 2q14 1,2 • IL1B gene encodes a protein 
member of the IL1 cytokine family, 
an important mediator of the 
inflammatory response.  
• Despite the role of inflammation in 
LOAD, the role of IL1B appears to 
be marginal. 
CLU 
[Harold et 
al., 2009] 
rs11136000 8p21.1 0,85 • CLU gene encodes for clusterin, 
which has a role in protecting the 
brain from damage, markedly 
influencing Aβ structure and its 
neuritic toxicity 
PICALM 
[Harold et 
al., 2009] 
rs541458, 
rs3851179 
11q14.2 0,87 • PICALM (phosphatidylinositol-
binding clathrin assembly) protein 
is involved in clathrin-mediated 
endocytosis, an essential step in 
the intracellular trafficking of 
proteins and lipids such as 
nutrients, growth factors and 
neurotransmitters. 
• changes in PICALM function result 
in perturbations at the synapse, 
possibly through synaptic vesicle 
cycling, increasing risk for AD.  
• PICALM could also influence AD 
risk through APP processing via 
endocytic pathways, resulting in 
changes in Aβ levels. 
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Gene Polymorphism location OR Relevance to AD pathogenesis 
KIBRA 
[Papassot
iropoulos 
et al., 
2006] 
rs17070145 5q n.a. • Associated with memory 
performance; 
• KIBRA T allele carriers show better 
episodic memory performance as 
compared with non carriers 
[Papassotiropoulos et al., 2006]; 
• KIBRA CC carriers had moderate 
but significantly increased risk of 
LOAD as compared to T-carriers 
[Corneveaux et al., 2008, 
Rodriguez-Rodriguez et al., 2009] 
TNK1 
[Figgins et 
al., 2009] 
rs1554948 17p13.1 0,86 • TNK1 encodes a nonreceptor 
tyrosine kinase involved in 
negative regulation of cell growth.  
• It has been reported that the SNP 
rs1554948 may be protective 
against LOAD. 
TFAM 
[Alvarez 
et al., 
2008] 
rs2306604 10q21 0,82 • TFAM encodes for mitochondrial 
transcription factor A that is a key 
activator of mitochondrial 
transcription as well as a 
participant in mitochondrial 
genome replication. 
• It can be considered a minor risk 
factor for LOAD. 
CR1 
[Lambert 
et al., 
2009] 
rs6656401 1q32 1,19 • CR1 encodes for a complement 
receptor 1, which could have roles 
in protecting the brain from 
damage.  
• Perhaps the SNP removes this 
protection. 
SORCS1 
[Grupe et 
al., 2006] 
rs600879 10q23–
q25 
1,24 • This gene encodes one member of 
vacuolar protein sorting 10 
domain-containing receptor 
proteins family.  
• These genes are strongly 
expressed in the CNS, but only 
one GWA studies suggested an 
involvement of this gene in LOAD. 
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As explained before, AD is a really genetically complex disorder, in which numerous 
genetic and environmental factors contributes with an individual small effect, resulting 
in the clinical expression of the disease only when their combined effects cross a 
“threshold of liability”. This complexity represents a great challenge for genetic 
studies. In addition to this genetic complexity, there is the fact that the brain is the 
most complex organ in the human body. Indeed, brain cells are different from each 
other, not only morphologically and functionally, but also in the connections and 
interactions between neurons and glia. Besides, the brain is also influenced by 
interactions between individuals and experiences. So, the clinical phenotypic 
expression of AD is subject to all these interactions, and it is not simply a sum of 
them. 
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Figure 1. Summary of the AD genes role (EOFAD and LOAD). 
 
APP gives rise to Aβ through serial cleavage by β-secretase and γ-secretase. γ-
secretase is a complex of proteins in which the enzymatic core is composed by 
PSEN1 and PSEN2.  
SORL1 and CH25H might both affect APP processing and Aβ generation, the first by 
affecting APP trafficking and the latter by the production of 25-hydroxycholesterol. 
GAB2 binds GRB2, which binds APP and presenilins.  
ApoE and CH25H genes, affecting cholesterol metabolism, with ACE gene, affecting 
blood pressure, might modulate the effects of cerebrovascular events on Aβ 
production. ApoE can also transport Aβ out of the brain and influence Aβ aggregation.  
Nicotinic cholinergic receptor subunit b2 (encoded by CHRNB2) might be affected by 
Aβ. Moreover, Aβ fibrillization can be affected by ApoE, Cystatin 3 (encoded by CST3) 
and prion protein (encoded by PRNP).  
Transferrin (encoded by TF gene) regulates the metabolism of iron, involved in 
oxidative stress, and associated with abnormal tau phosphorylation and aggregation, 
and with the formation of neurofibrillary tangles.  
The principal component of neurofibrillary tangles is tau, which is encoded by MAPT 
gene. GAB2 also has been reported to affect tau phosphorylation and NFT formation. 
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Endophenotypes in Alzheimer’s disease 
Despite the improvement of genome data analysis techniques, the research of genetic 
variants associated with LOAD is still limited. Why has the pursuit of susceptibility 
LOAD genes been so difficult and elusive? 
The first greatest problem that affects genetic studies of AD, as well as other 
psychiatric disorders in general, is that various types of phenotypic misclassification  
could occur, thus reducing the power of the analyses. Labeling affected family 
members as ʻunaffectedʼ reduces the apparent penetrance, so larger sample sizes are 
required to obtain significant results. Conversely, labeling unaffected family members 
as ʻaffectedʼ masks the presence of linkage, making detection of linkage more difficult 
and specific localization of susceptibility genes almost impossible. 
Besides, there is heterogeneity both in the clinical presentation of AD and in the 
genetic background of the subjects. Finally, sample sizes in most genetic association 
studies may be too small to have adequate statistical power in this complex disease in 
which multiple genes with small effect each contribute to the different traits associated 
with the disease, such as memory performance, amyloid/tau pathology or 
hippocampal atrophy. 
The genetic analysis in AD might be improved by the identification of more basic 
phenotypes than the full phenotypic expression of AD, for which a more 
homogeneous etiology might be expected. These AD intermediate phenotypes, or 
endophenotypes, are generally closer to the action of the gene than the affection 
status, and thus exhibit higher genetic signal-to-noise ratio (Figure 2) [Gottesman et 
al., 2003, Reitz et al., 2009]. 
In AD the identification of the endophentypes could be achieved with two strategies: 
the description of AD affected patients and the identification of vulnerability traits in 
non-affected AD relatives. This second approach is particularly interesting in AD, 
indeed the subclinical endophenotypes might be useful for identifying common alleles 
with non-specific and moderate effects on diseases risk [Matthysse et al., 1992, 
Leboyer et al., 1998]. The first approach, instead, could be described as the 
“candidate symptom approach” [Gottesman et al., 2003]. The description and analysis 
of affected subjects could help in identifying AD subgroups. For example, in AD, the 
mutations in genes encoding for APP, PSEN1 and PSEN2 were identified only after 
the selection of early-onset familial cases of AD showing an autosomal pattern of 
inheritance. 
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For all these reasons, only through the identification of endophenotypes in AD we can 
increase the power to localize and identify AD related susceptibility genes, more easily 
than using the affection status alone [Blangero et al., 2003].  
 
Possible AD endophenotypes, which may be more proximal to its genetic variations, 
could be particular profiles of clinical onset of the disease, or typical characteristics of 
cognitive impairment, or the presence or distribution of the typical AD pathological 
alterations. Some AD endophenotypes can be measured in vivo using neuroimaging 
techniques, which could be capable to highlight the presence of specific alterations 
usually observed in patients with clinically manifest AD. Among the pathological 
changes and the corresponding neuroimaging examinations, there are (Figure 2): 
- morpho-structural brain changes, measurable with brain magnetic resonance 
imaging (MRI); 
- brain synaptic disfunction, measurable using positron emission tomography (PET) 
with 18F-fluorodesoxyglucose (18F-FDG); 
- deposition and accumulation of pathological proteins, such as amyloid and tau 
proteins, measurable using PET with amyloid tracers such as 11C-PiB. 
 
Figure 2. Endophenotypes in the cascade from a genetic sequence variation and 
AD. 
 
  
	   17 
Maternal family history of AD 
Several epidemiological studies in AD have shown that, besides AD heritability, 
maternal transmission may have a greater impact on the offspring’s health than 
paternal transmission. This is not only due to the fact that AD affects more women 
than men [Green et al., 2002], but that maternal transmission is actually more frequent 
than paternal transmission of AD [Gomez-Tortosa et al., 2007]. A review of the AD 
literature [Duara et al., 1993; Edland et al., 1996; Heyman et al., 1983; Farrer et al., 
1997] shows that approximately 20% of LOAD cases are maternally inherited and, in 
LOAD patients with one affected parent, the mother-to-father ratio is approximately 
3:1 [Heyman et al., 1983, Duara et al., 1993, Edland et al., 1996, Farrer et al., 1997, 
Gomez-Tortosa et al., 2007]. Importantly, having an AD-affected mother was 
associated with poorer cognitive performance in late life [Schifitto et al., 2007] and 
with a more predictable age at onset of dementia in the offspring, as compared to 
having an AD-father [Duara et al., 1993, Gomez-Tortosa et al., 2007, Duara et al., 
1996]. 
Among many possible explanations about this particular pattern of inheritance, the 
most likely genetic mechanisms to explain maternally inherited AD would appear to be 
(in alphabetical order): 
•  chromosome X-mediated transmission 
•  epigenetic imprinting 
•  mitochondrial DNA-mediated transmission 
•  sex-specific trinucleotide repeat expansions-mediated transmission. 
 
Chromosome X-mediated transmission 
Chromosome X-linked diseases are disorders that reflect the presence of defective 
genes on the X chromosome. The vast majority of X-linked diseases show recessive 
transmission with the following features:  
1) males are more frequently affected than females because they are hemizygous and 
the gene defect is not balanced by a normal X chromosome;  
2) females are rarely affected because they need to be homozygous for the defective 
gene to manifest the phenotype; 3) there is no male-to-male transmission;  
4) transmission of the defective gene occurs from fathers to daughters, who become 
carriers;  
5) males born to a carrier mother have a 50% probability of inheriting the X 
chromosome carrying the defective gene.  
	   18 
Classical examples of X-linked transmission are red–green colour blindness and 
haemophilia A. 
The ‘X-linked hypothesis’ for a LOAD gene was supported by a recent genome-wide 
association study, which identified a strong association between LOAD and a 
mutation located on the PCDH11X  gene on chromosome X.64  Female homozygotes 
were at significantly increased risk for AD compared with female non-carriers, female 
heterozygotes and male hemizygotes. Moreover, female heterozygotes were at greater 
risk than female non-carriers, and male hemizygotes were at higher risk than male 
non-carriers [Carrasquillo et al., 2009]. 
 Although maternally inherited LOAD and X-linked diseases may share some 
characteristics, several properties of recessive X-linked disorders do not apply to AD. 
First, PCDH11X  mutations were associated with higher risk in female homozygotes 
than male hemizygotes, which is contrary to what is usually found in X-linked 
recessive disorders. Secondly, there is no male-to-male transmission in X-linked 
inheritance, whereas father-to-son transmission has been reported in AD [Ehrenkrantz 
et al., 1999; Gomez–Tortosa et al., 2007].  
 
Epigenetic imprinting 
Genomic imprinting is a genetic process by which certain genes are expressed in a 
parent-of-origin specific manner, which does not follow classical Mendelian 
inheritance [Constancia et al., 2004]. One of the most common mechanisms of 
genomic imprinting is the silencing of one of the parental alleles, and gene expression 
is monoallelic. This silencing mechanism is known to involve epigenetic marking by 
allele-specific DNA methylation and/or histone modifications. Differential epigenetic 
marking of the parental chromosomes results in differential gene expression, 
predominantly from one parental allele.  
For a gene that is normally imprinted with paternal silencing, a mutation in the 
maternal copy of the gene will result in disease, while a mutation in the paternal copy 
will have no effect, and vice versa. According to the parental conflict hypothesis, 
paternal imprinting appears to be growth promoting, while maternal imprinting would 
be growth limiting. 
Imprinted genes are susceptibility targets for numerous human pathologies because 
their functional haploid state enables a single genomic or epigenomic change to 
dysregulate their function. Recent evidence has highlighted the role of genetic 
imprinting on brain function for PraderWilli and Angelman syndromes, as well as more 
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common disorders like diabetes, obesity, breast cancer, autism, bipolar disorder, 
Tourette’s syndrome, epilepsy and even AD [Constancia et al., 2004]. 
Maternal imprinting may be a genetic mechanism responsible for the increased 
maternal inheritance in AD cases. Some reports showed that the methylation process 
involved in imprinting is altered in AD patients, compared with controls [Payao et al., 
1998]. A genome-wide screening of AD families reported a linkage between AD and a 
region close to the centromere of chromosome 10q only in families with an AD 
affected mother [Basset et al., 2002].  While these findings suggest imprinting, there is 
no clear evidence for the existence of imprinted genes in AD families on chromosome 
10 or on other chromosomes. 
 
Mitochondrial DNA 
Mitochondrial disorders are entirely maternally inherited in humans and are 
characterised by variable phenotypic expression. Male and female progeny are equally 
likely to receive mutant maternal mitochondrial DNA (mtDNA).  
The fact that mtDNA is exclusively maternally inherited in humans lends support to 
this hypothesis [Lin et al., 2006, Swerdlow et al., 2004]. 
Human mtDNA is a 16.569-kb circular, double-stranded molecule, containing 37 
genes: 2 rRNA genes, 22 tRNA genes and 13 structural genes that encode electron 
transport chain (ETC) subunits. Of the approximately 80 proteins that make up the 
ETC, 13 are encoded by mtDNA and all others are encoded by nuclear DNA, such as 
complex II, coenzyme Q and cytochrome c. In contrast, the catalytic components of 
complex I, III, IV and V are primarily encoded by mtDNA, which contains 7 genes 
encoding for complex I (ND1-ND4, ND4L, ND5 and ND6), 1 for complex III 
(cytochrome b), 3 for complex IV (COX I-III) and 2 for complex V (ATPase6 and 
ATPase8). Although mtDNA encodes for only 2% of all proteins forming the subunits 
of the mitochondrial respiratory chain, all of them are essential for maintaining 
physiological oxidative phosphorylation (OXPHOS). For more than 15 years, evidence 
has been accumulating that AD is associated with mitochondrial dysfunction, as well 
as oxidative stress and increased reactive oxygen species (ROS) production. At post-
mortem, extensive oxidative stress is found in AD brains, in which basically all cellular 
macromolecules (protein, DNA, lipids) are found in an oxidized form [Smith et al., 
1995., Mecocci et al., 1994.]. Oxidative stress, particularly in the form of reduced COX 
activity, is most prominent in the brain regions showing degeneration in AD [Kish et al., 
1992, Valla et al., 2001, Simonian et al., 1994.]. 
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Reduced COX activity in AD was shown in several in vivo studies of blood platelets 
[Parker et al., 1994, Bosetti et al., 2002] and fibroblasts [Curti et al., 1997].  
Studies that investigated the role of mtDNA mutations in AD have used three main 
approaches: i) cybrid analyses; ii) case-control mutation identification studies; iii) 
mitochondrial haplogroup association studies. Studies of cytoplasmic hybrid (cybrid) 
cells provide direct evidence for mtDNA involvement in the metabolic abnormalities 
characteristic of AD. Cybrids are obtained by mixing mtDNA from patientsʼ platelets 
with cell lines depleted of their own endogenous mtDNA, resulting in cell lines 
containing mtDNA from the patient [Lucas et al., 1976]. Cybrid data in AD indicate that 
mtDNA at least partly accounts for impaired metabolism and increased oxidative 
stress in AD, as reflected in increased ROS production, mitochondrial respiratory 
enzymes defects, particularly affecting COX activity, increased changes in calcium 
homeostasis, decreased ATP production and enhanced Aß toxicity, and a vastly 
increased percentage of morphologically abnormal mitochondria [Swerdlow et al., 
1997, Cardoso et al., 2004]. In addition to cybrid studies, several case-control 
mutation identification and mitochondrial haplogroup association studies suggested 
that maternally inherited mutations of mtDNA might play a pathogenic role in AD 
(Table 3). However, despite the observation of mtDNA mutations in AD vs controls and 
of associations observed between specific haplotypes and an increased risk for AD, 
the overall involvement of mtDNA in AD pathogenesis is equivocal because of 
conflicting results. 
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Table 3. Mitochondrial DNA mutations and haplotypes associated with LOAD. 
 
Approach Finding Positive results Negative results 
Case-control 
mutation 
identification 
T146G, T195C, 
T152C, A189G, 
T414G 
Increased AD risk [Coskun et 
al., 2004] 
No mutation found 
[Chinnery et al., 
2001] 
4977 bp 
deletion 
More frequent in AD patients 
[Corral-Debrinski et al., 1994.] 
 
A4336G More frequent in AD patients 
[Egensperger et al., 1997, 
Shoffner et al., 1993.] 
No association with 
AD [Wragg et al., 
1995.] 
Haplogroup 
association 
K, U Decreased risk of AD, 
neutralizing the effect of ApoE 
genotype [Carrieri et al., 2001.] 
No effect of K 
haplogroup in AD 
[van der Walt et al., 
2004.] 
U Increased risk in males, 
decreased risk in females [van 
der Walt et al., 2004.] 
 
J Increased in AD patients in a 
French-Canadian population 
[Chagnon et al., 1999.] 
No AD haplogroup 
association in US 
population 
[Chinnery et al., 
2001] 
T  Decreased AD risk in a French-
Canadian population [Chagnon 
et al., 1999] 
No AD haplogroup 
association in US 
population 
[Chinnery et al., 
2001] 
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Sex–specific trinucleotide repeat expansions 
Trinucleotide repeat disorders (TRD) are a class of molecular diseases characterised 
by the presence of unstable and abnormal expansions of DNA triplets (trinucleotides). 
Generally, the larger the expansions, the more likely they are to cause disease or 
increase the severity of disease. This property results in the phenomenon of genetic 
anticipation, as is evident in TRDs, in which there is a tendency for age of onset to 
decrease and severity of symptoms to increase through successive generations of an 
affected family, due to the expansion of these repeats [Brower et al., 2009].  
Large increases or expansions in the number of trinucleotide tandem repeats are 
involved in a number of inherited neurodegenerative conditions, which appear to be 
specific to the gender of the transmitting parent. For example, in Huntington’s disease 
there is an increased number of CAG repeats, and this condition is preferentially 
paternally inherited [Kehoe et al., 1999]. Some neurological TRDs show a preferential 
maternal transmission, such as fragile X syndrome [Mandel et al., 2004], Friedreich 
ataxia [La Pean et al., 2008], spinocerebellar ataxia type and myotonic dystrophy 
[Botta et al., 2009]. There is currently no evidence for trinucleotide repeat expansions 
in AD. 
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Hypotheses 
Previous neuroimaging studies have shown that the specific brain alterations 
observed in AD patients occur also at the stage of mild cognitive impairment due to 
AD and even in normal individuals with genetic risk factors for AD, such as ApoE ε4 
carriers. 
In particular, several MRI studies in mild cognitive impariment and at-risk individuals 
demonstrated the presence of reduced grey matter volume in cortical regions usually 
affected in AD patients, such as precuneus/posterior cingulate and parieto-temporal 
regions. The grey matter volume reduction in these AD-vulnerable regions has been 
associated with increased risk for developing AD among normal individuals [Chen et 
al., 2007; Chetelat et al., 2005; Jack et al., 2005; Reiman et al., 1998]. 
Another consistent AD feature is the reduction of cerebral metabolism involving the 
parieto-temporal, precuneus/posterior cingulate cortices, and medial temporal lobes. 
Such metabolic reductions within these regions have been demonstrated to occur 
years before AD symptom onset, even in normal individuals at genetic risk of 
developing AD and predict clinical cognitive decline in mild cognitive impairment 
patients [Jagust et al., 2006; Mosconi et al., 2009]. 
Finally, a cardinal neuropathological feature in AD is fibrillar Aβ deposition in senile 
plaques. There are several PET tracers with high affinity for Aβ senile plaques; among 
them the most known is Pittsburgh Compound B (PiB). High PiB retention in amyloid-
rich regions has been observed not only in AD patients, but also in many patients with 
mild cognitive impairment, and seems to be associated with conversion from mild 
cognitive impairment to AD [Kemppainen et al., 2007; Reiman et al., 2009]. 
Our hypothesis was that the presence of AD-specific alterations observed using 
neuroimaging techniques could be present also in cognitively normal individuals with a 
maternal family history of AD, thus providing a biological endophenotypes related to 
maternally transmitted risk of AD. 
In particular, this project examinated wheter normal individuals with an AD-affected 
mother showed brain changes similar to those observed in AD patients, such as:  
- reduced grey matter volume in AD-specific regions; 
- cerebral metabolic reductions in AD-vulnerable regions; 
- increased cortical Aβ load.  
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Materials and Methods 
Subjects 
Seventy-five clinically and cognitively normal subjects were recruited both at Azienda 
Ospedialiero-Universitaria Careggi, Florence, italy, and at New York University School 
of Medicine, New York, USA. These included individuals interested in risk consultation 
and research participation, spouses, family members, and caregivers of patients. 
All subjects received a standard diagnostic evaluation that included medical, 
neuropsychological, and MRI examinations. Institutional Review Board (IRB)-approved 
informed consent was obtained from all subjects. Individuals with medical conditions 
or history of conditions that may affect brain structure or function, i.e., stroke, 
diabetes, head trauma, any neurodegenerative diseases, depression, hydrocephalus, 
intracranial mass, and infarcts on MRI, and use of psychoactive medications were 
excluded. 
Subjects had age < 45 years, education>13 years, Clinical Dementia Rating (CDR)=0, 
Global Deterioration Scale (GDS)<2, Modified Hachinski Ischemia Scale scores<4, and 
Mini Mental State Examination (MMSE)>28. All subjects had normal cognitive test 
performance relative to normative values on neuropsycological examination. 
Subjects with FHm (i.e., only the mother was affected with AD), FHp (i.e., only the 
father was affected with AD), and FH- (i.e., negative FH) were included in the study. 
Demographic characteristics of the subjects under study are shown in Table 4. Age, 
gender, education were included as covariates in all analyses, as described below. 
There were no differences across FH groups for age, gender, education, MMSE 
scores and neuropsychological test performance. 
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Table 4. Subjects demographic and clinical characteristics. 
 FH- FHp FHm 
N 25 25 25 
Age, years 65.5±8.9 62.9±12.1 63.0±7.8 
Gender (male/female) 14/11 13/12 15/10 
Education, years 16.4±2.2 16.9±2.0 17.2±1.6 
MMSE 29.4±0.8 29.6±0.8 29.6±0.8 
Values are mean ± SD. 
 
 
MRI acquisition and processing 
All subjects received an MRI study on a 1.5 T MRI scanner. The scan was a 124 slice 
T1-weighted fast-gradientecho acquired in a sagittal orientation as 1.2-mm thick 
sections. These scans were used to rule out MRI evidence of hydrocephalus, 
intracranial mass, strokes, subcortical gray matter lacunes, nonspecific white matter 
disease, and focal white matter hyperintensities. MRI images were analyzed with 
voxel-based morphometry (VBM) using MATLAB 7.8 (the MathWorks, Natick, MA, 
USA) and Statistical Parametric Mapping (SPM8) (Wellcome Trust Centre for 
Neuroimaging, University College London). For all subjects, MRI images were spatially 
normalized to the SPM template in the stadardized anatomical space, which conforms 
to the Montreal Neurological Institute (MNI) space, by estimating the optimum (least 
squares) 12-parameter affine transformation, followed by 7x8x7 discrete cosine 
functions. A masking procedure was used to weight the normalization to brain rather 
than non-brain tissue. The spatially normalized MRI images were segmented into gray 
matter (GM), white matter, and cerebrospinal fluid images using SPM8’s unified tissue 
segmentation procedure which rely on an iterative process to determine proportions 
of GM and white matter in each voxel, after removal of all non-brain voxels and 
application of image intensity nonuniformity correction. The GM images were retained 
for analyses and normalized to an a priori GM template by using the same 
normalization parameters described above. To preserve GMV within each voxel, the 
images were modulated by the Jacobian determinants derived from the spatial 
normalization, and then smoothed using an 8-mm full width at half maximum (FWHM) 
isotropic Gaussian kernel. GM, white matter, and cerebrospinal fluid segmentations 
for each image were used to calculate the total intracranial volume (TIV) for each 
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subject. The TIV was computed in cubic centimeters and examined examined as a 
covariate in subsequent analyses. 
 
18F-FDG PET acquisition and processing 
Each subject received a brain PET scan using 18F-FDG as the tracer. Subjects 
received 5–8 mCi of 18F-FDG intravenously while lying in a dimly lit room. Each 
subject’s head was positioned by using two orthogonal laser beams and imaged with 
the scanner tilted 25° negative to the canthomeatal plane. PET images were obtained 
30 min after injection and acquired over 20-minutes acquisition. Data were 
reconstructed by using filtered back-projection and corrected for attenuation, scatter, 
and radioactive decay, yielding a 128x128 matrix. 
Image Analysis. Statistical parametric mapping (SPM5; Wellcome Department of 
Neurology, London, U.K.) was used for image analysis. 18F-FDG-PET images were 
spatially normalized to a standard FDG-PET brain template in the Montreal 
Neurological Institute space, which approximates the Talairach and Tournoux space. 
The spatial normalization process involves estimating the optimum least-squares 12-
parameter affine transformation, followed by an iterative estimate of local alignment 
based on a family of 7x8x7 discrete cosine functions. The spatially normalized PET 
images were then resampled with a voxel size of 1.5x1.5x1.5 mm and smoothed with 
a 12-mm FWHM Gaussian filter. Only voxels with values>80% of the whole mean 
metabolic values were included in the analysis, and only clusters exceeding an extent 
threshold of 30 voxels (i.e., more than two times the FWHM) were considered 
significant. Global calculation was obtained with respect to the mean voxel value while 
accounting for global metabolism. Anatomical location of brain regions showing 
significant effects was described by using the Talairach and Tournoux coordinates 
using Talairach Daemon 12.0 after coordinates conversion from the Montreal 
Neurological Institute space to the Talairach space using linear transformation.  
 
11C-PiB PET acquisition and processing 
N-methyl[11C]2-(4′-methylaminophenyl)-6-hydroxy-benzothiazole (PiB) as the tracer. 
PiB was synthesized on site from the reaction of 6-OH-BTA-0 and [11C]methyl triflate. 
Radiochemical purity of the radioligand was >98%. Before PET imaging, an 
antecubital venous line was positioned for isotope injection. Subjects were rested with 
eyes open and ears unplugged in the quiet and dimly lit scan room. After injection of 
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15 mCi (∼550 MBq) of PiB, subjects were positioned in the scanner using laser light 
beams for head alignment. Total scanning time was 90 min. All images were corrected 
for photon attenuation, scatter, and radioactive decay and were reconstructed into a 
128x128 matrix spaced every 4.25 mm. Image processing and data analyses were 
performed at NYU. Summed PET images corresponding to the 60–90 min of PiB data 
were created for both data sets and were coregistered to T1-MRI using a surface-
fitting algorithm implemented in MIDAS 1.9. Standardized uptake values (SUV) were 
determined on a voxel-wise basis. A cerebellar GM region was delineated on MRI and 
used as the reference to correct (normalize) for nonspecific tracer binding by dividing 
each voxel’s SUV into the cerebellar SUV, yielding parametric PiB SUV ratio (SUVR) 
images. Parametric PiB SUVR images were processed using SPM5 and automated 
ROI. Briefly, subjects’ MRIs were normalized spatially to a standardized MRI brain 
template image, which approximates the Talairach and Tournoux space, by estimating 
the optimum least-squares, 12-parameter affine transformation, followed by 7x8x7 
cosine functions. These parameters were applied to MRI-coregistered PiB scans to 
generate spatially normalized PiB SUVR images. Automated ROIs were used to 
sample GM within AD-related brain regions, including the anterior putamen, IPL, LTL, 
medial frontal gyrus, PCC/precuneus, PFC, OCC, and thalamus. A cortical PiB 
retention mask (AD-mask) also was created by combining the cortical ROIs.  
Spatially normalized PiB images then were smoothed with a 12-mm Gaussian filter 
and were examined for voxel-wise effects acrossgroups. As a result of the cerebellar 
normalization of PiB data, no proportional scaling or grand mean scaling was 
performed. A GM mask was generated from the SPM5 a priori GM template by 
retaining voxels with values ≥0.8 (i.e., the probability of the voxel’s contents 
beingGMwas≥80%) and was included as an explicit mask to perform group 
comparisons exclusively within GM voxels. Only clusters of 30 or more voxels were 
considered significant. 
 
Statistical analysis 
SPSS and SPM were used for data analyses. Differences in clinical and 
neuropsychological measures between FH groups were examined with chi-square 
tests and the general linear model (GLM) with post hoc least significant difference 
(LSD) tests, as appropriate. Results were considered significant at p<0.05.  
For SPM analysis, the GLM/univariate analysis with post hoc t  tests was used to test 
for GMV differences across FH groups. Additionally, analyses were repeated 
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correcting for other potential risk factors for AD, such as age, gender, education, by 
including these variables as nuisance variables (i.e., covariates) in the GLM.  
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Results 
MRI 
FHm subjects showed reduced GMV compared with both FH- and FHp (Table 5). As 
compared with FH-, FHm subjects showed significant GMV reductions in the inferior 
parietal cortex and precuneus of the left hemisphere, and in superior temporal cortex 
and inferior frontal gyrus of the right hemisphere (p<0.05, FWE-corrected) (Figure 3, 
Table 5).  
As compared with FHp, FHm subjects showed reduced GMV in the left precuneus 
(p<0.05, FWE-corrected) (Figure 3, Table 5).  
FHm had on average 15% reduced GMV compared with FH- (ranging from 13% in 
superior temporal to 16% in inferior frontal gyrus), and 15% reduced GMV in 
precuneus compared with FHp. 
FHp subjects showed no regions of reduced GMV as compared with FH- and FHm. 
No GMV decreases were found in FH- subjects compared with FHm or FHp subjects. 
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Table 5. Brain regions showing significant differences in gray matter volume 
between FH groups 
 
 
Cluster 
extent 
Coordinates* Z value** Functional area Brodmann 
Area 
Reduced gray matter volume in FHm compared to FH- 
4049 -57   -47    38  4.88 left Inferior Parietal Lobule 40 
 -36   -60    47  4.76 left Inferior Parietal Lobule 7 
 -40   -65    40  4.45 left Inferior Parietal Lobule 39 
  x x x Left Precuneus 19 
1175  40    50    -1  4.72 right Inferior Frontal Gyrus   10 
  48    36    22  4.40 right Middle Frontal Gyrus  46 
    36    56    -3  4.34 right Middle Frontal Gyrus 10 
Reduced gray matter volume in FHm compared to FHp  
317 -34   -74    39  4.54 left Precuneus 19 
* Coordinates (x, y, z) from the atlas of Talairach and Tournoux 17;  
**Z value at the peak of statistical significance, P<0.05, FWE-corrected. 
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Figure 3. Statistical parametric maps showing gray matter volume (GMV) 
reductions in cognitively normal individuals (NL) with maternal family history 
(FHm) compared with NL with negative family history (FH_) (in blue-green) and 
paternal family history (FHp) (in violet). 
 
 
From Berti et al. Neurobiol Aging 2011 
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18F-FDG PET 
As compared with FH-, FHm subjects showed brain metabolic reductions bilaterally in 
the inferior parietal lobe and middle temporal gyrus, and in the PCC/precuneus, 
superior frontal gyrus, and medial temporal lobe of the left hemisphere (P<0.05, SVC) 
(Table 6 and Figure 4). Metabolic reductions ranged from 8% in the left superior frontal 
gyrus to 22% in the left PCC.  
As compared with the FHp group, the FHm group showed reduced cortical 
metabolism bilaterally in the middle and superior temporal gyrus, and in the left 
PCC/precuneus and medial temporal lobe (P<0.05, SVC) (Table 6 and Figure 4). 
Metabolic reductions ranged from 5% in the right middle temporal gyrus to 27% in the 
PCC/precuneus. 
 
 
 
Figure 4. Statistical parametric maps showing CMRglc reductions in normal FHm 
subjects as compared with FH- (Upper) and FHp (Lower) subjects. 
 
 
 
From Mosconi et al. PNAS 
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Table 6. Brain regions showing significant hypometabolism in subjects with 
maternal family history of AD as compared with the other groups 
 
Cluster extent Coordinates* Z values Functional area BA 
CMRglc reductions in FHm subjects as compared with FH- subjects 
1,056 _4, _70, 24 2.86 Precuneus 7 
 _3, _67, 20 2.75 PCC 31 
710 _43, _35, 39 2.69 Inferior parietal 
lobe 
40 
 _39, _56, 30 2.63 Inferior parietal 
lobe 
40 
 _61, _48, _4 2.60 Superior 
temporal gyrus 
21 
569 _28, _23, _8 2.70 Hippocampus 
 
 
 _20, _21, _12 2.65 Parahippocampal 
gyrus 
35 
 _21, _24, _8 2.35 Parahippocampal 
gyrus 
28 
357 52, _52, 32 3.23 Inferior parietal 
lobe 
40 
300 _23, 54, 4 2.75 Superior frontal 
gyrus 
10 
237 62, _43, _8 2.55 Superior 
temporal gyrus 
21/37 
 63, _46, _4 2.52 Middle temporal 
gyrus 
21 
171 _55, 2, _8 2.97 Middle temporal 
gyrus 
21 
CMRglc reductions in FHm subjects as compared with FHp subjects 
231 _25, _29, _8 3.08 Hippocampus 
 
 
 _19, _28, _8 2.39 Parahippocampal 
gyrus 
28/35 
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676 _65, _16, 8 4.09 Middle temporal 
gyrus 
22 
 _64, _32, _4 3.38 Superior 
temporal gyrus 
21 
873 7, _61, 8 3.63 Cingulate gyrus 23/30 
 4, _58, 12 3.49 Cingulate gyrus 23 
510 64, _26, _8 3.40 Middle temporal 
gyrus 
21 
410 _4, _71, 24 2.69 Precuneus 7 
 _3, _65, 21 2.55 PCC 31 
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11C-PiB PET 
As compared to FH-, FHm subjects showed higher PiB retention in middle frontal 
gyrus, prefrontal cortex, inferior frontal gyrus, PCC/precuneus, anterior cingulate 
cortex (ACC), temporal, parietal, and occipital cortex, and fusiform gyri bilaterally, and 
in basal ganglia and thalamus of the right hemisphere.  
As compared to FHp, FHm subjects showed higher PiB retention in the bilateral 
PCC/precuneus, inferior parietal lobe, prefrontal cortex, ACC, and in the left temporal, 
occipital, middle frontal gyrus, and inferior frontal gyrus (Figure 5).  
The FHp group showed higher PiB retention than the FH- group in the middle frontal 
gyrus and PCC/precuneus, mostly of the left hemisphere.  
No brain regions showed significantly higher PiB retention in the FH- group as 
compared with the FHm or FHp groups or in the FHp group as compared 
with the FHm group.  
Overall, PiB retention was higher in all brain regions in the FHm group, than in the FHp 
and FH- groups. 
 
 
Figure 5. SPMs showing higher PiB retention in FHm subjects than in FH− and 
FHp subjects (Top Two Rows) and in FHp subjects than in FH− subjects (Bottom 
Two Rows).  
 
 
From Mosconi et al. PNAS 2010 
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Discussion 
The present neuroimaging study demonstrated the presence of cerebral changes, 
which are tipically observed in AD patients, in adult children of parents affected with 
AD. Specifically, cognitively normal individuals with AD maternal family history 
consistently showed brain alterations, such as brain atrophy, cortical hypometabolism 
in AD-vulnerable regions and increased Aβ accumulation as compared with subjects 
of similar demographic characteristics with paternal family history and negative family 
history for AD. 
Previous studies have already shown that precuneus/posterior cingulate and parieto-
temporal regions are affected in AD patients compared with controls. AD patients 
demonstrated variable degree of cortical atrophy involving precuneus/posterior 
cingulate cortex, medial temporal lobes and parieto-temporal regions [Convit et al., 
2000; Hirata et al., 2005]. Another main characteristic of AD patients is the reduction 
of cerebral metabolism in the same specific brain areas, such as precuneus and 
posterior cingulate [Minoshima et al., 1997], parieto-temporal cortex [Friedland et al., 
1983] and medial temporal cortices [Mosconi et al., 2006], and in advanced stages of 
the disease in the frontal lobe [Foster et al., 1984]. Finally, high 11C-PiB retention in 
amyloid-rich regions is observed consistently in AD patients, involving extensively 
cortical and subcortical areas [Klunk et al., 2004]. 
Our findings in FHm subjects are consistent with the presence of AD-typical brain 
changes, as shown by MRI, 18F-FDG and 11C-PiB PET, observed in presymptomatic 
individuals carrying genetic mutations responsible for early onset familial AD, as well 
as normal subjects carriers of the ApoE-ε4 allele, a major genetic risk factor for AD 
[Reiman et al., 1998; Reiman et al., 1996; Reiman et al., 2009]. 
Atrophy and hypometabolism in AD-vulnerable regions and cerebral accumulation of 
fibrillar amyloid also accurately predict decline from mild cognitive impairment to AD, 
as recently confirmed in several neuroimaging studies [Chetelat et al., 2005; Mosconi 
et al., 2009; Okello et al., 2009]. 
Togheter with such previous findings, our results of AD-typical brain changes in 
cognitively normal FHm individuals compared with FH- and FHp suggest that having a 
mother affected by AD may be associated with increased risk for preclinical brain 
volume loss, preclinical brain metabolic impairment and preclinical accumulation of 
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fibrillar Aβ; they may be associated also to an increased risk for developing AD, 
compared with having a father affected with AD. 
Moreover, according to our data, FHm subjects appear to be at a more advanced 
stage of both brain amyloidosis, metabolic impairment and cortical atrophy as 
compared to FHp and FH- individuals.  
Collectively, our MRI, 18F-FDG and 11C-PiB results demonstrated that FHm 
individuals have significant cortical atrophy, metabolic reductions and increased Aβ 
load in AD regions as compared to FH- subjects, whereas FHp individuals of the same 
age range have some Aβ deposits in the absence of hypometabolism and atrophy. 
These data could suggest that amyloidosis may precede neuronal dysfunction in FHp 
subjects. On the other hand, the presence of both Aβ pathology, hypometabolism and 
atrophy in middle-aged to old normal FHm subjects indicates that these brain 
abnormalities and thus the process leading to neuronal dysfunction and subsequent 
loss may have developed at younger ages in these subjects; it is also relatively 
independent from other possible risk factors for AD such as age, gender, education, 
and ApoE status.. 
Longitudinal studies are needed to determine wheter the observed brain abnormalities 
in normal FHm subjects are predictive of future cognitive impairment in these 
individuals. 
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Conclusion 
In conclusion, during this project we observed using neuroimaging techniques the 
presence of AD-specific brain abnormalities in cognitively normal individuals with a 
maternal family history of AD, thus providing a biological endophenotypes related to 
maternally transmitted risk of AD. 
In particular, our data demonstrated that normal individuals with an AD-affected 
mother showed brain changes similar to those observed in AD patients, such as:  
- reduced grey matter volume in AD-vulnerable regions; 
- cerebral metabolic reductions in AD-vulnerable regions; 
- increased cortical Aβ load.  
These findings may indicate that cognitively normal FHm subjects may be a group of 
individuals at particularly high risk for AD by virtue of developing brain 
hypometabolism, atrophy, and amyloid-beta pathology prior to their age-matched 
peers with different family histories.  
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